Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12.

OBJECTIVE Studies have shown that in systemic sclerosis (SSc) endothelial cells, overproduction of matrix metalloproteinase 12 (MMP-12) and pentraxin 3 (PTX3) is associated with defective angiogenesis. This study was undertaken to examine whether overexpression of the relevant molecules could inhibit angiogenesis of normal microvascular endothelial cells (MVECs), and whether silencing of these molecules in SSc MVECs could restore the lost angiogenic properties of the cells in vitro and in vivo. METHODS Transient transfection of MVECs with human MMP12 and PTX3 was performed by electroporation. Silencing of MMP12 and PTX3 was obtained by treatment with small interfering RNA, and treatment effects were validated by Western blotting with specific antibodies and a fluorimetric assay. In vitro cell migration and capillary morphogenesis were studied on Matrigel substrates. In vivo angiogenesis was studied using a Matrigel sponge assay in mice. RESULTS Transfection of MMP12 and PTX3 in normal MVECs resulted in loss of proliferation, invasion, and capillary morphogenesis in vitro, attributed to truncation of the urokinase-type plasminogen activator receptor by MMP12 and to the anti-fibroblast growth factor 2/anti-vascular endothelial growth factor activity of PTX3. These effects were particularly evident in mixed populations of transfected normal MVECs (50% transfected with MMP12 and 50% with PTX3). Silencing of the same molecules in SSc MVECs increased their invasion in Matrigel. Single-gene silencing did not increase the capillary morphogenesis of SSc MVECs, whereas double-gene-silenced cells showed a burst of capillary tube formation. Culture medium of silenced SSc MVECs stimulated angiogenesis in assays of Matrigel sponge invasion in mice. CONCLUSION Overexpression of either MMP12 or PTX3 in normal MVECs blunts their angiogenic properties. Loss of function of MMP12 and PTX3 in SSc MVECs restores the ability of the cells to produce capillaries in vitro and induces vascularization in vivo on a Matrigel sponge.

[1]  N. Sidenius,et al.  The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. , 2008, European journal of cell biology.

[2]  Marco Presta,et al.  Role of the soluble pattern recognition receptor PTX3 in vascular biology , 2007, Journal of cellular and molecular medicine.

[3]  Bernd R Binder,et al.  uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view , 2007, Thrombosis and Haemostasis.

[4]  B. Rothen‐Rutishauser,et al.  Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: Endothelial versus epithelial features , 2001, In Vitro Cellular & Developmental Biology - Animal.

[5]  D. Nosi,et al.  Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. , 2006, Arthritis and rheumatism.

[6]  S. Bombardieri,et al.  Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP‐12‐dependent cleavage of the endothelial cell urokinase receptor , 2006, The Journal of pathology.

[7]  B. Giusti,et al.  A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients , 2006, Arthritis research & therapy.

[8]  B. Giusti,et al.  The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. , 2005, Arthritis and rheumatism.

[9]  Christian Wittekind,et al.  Cancer Invasion and Metastasis , 2005, Oncology.

[10]  P. Maxwell.  The HIF pathway in cancer. , 2005, Seminars in cell & developmental biology.

[11]  P. Comoglio,et al.  Sema4D induces angiogenesis through Met recruitment by Plexin B1. , 2005, Blood.

[12]  A. Angelucci,et al.  Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases , 2005, Gene Therapy.

[13]  M. Cinelli,et al.  Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. , 2004, Arthritis and rheumatism.

[14]  Y. Ikeda,et al.  Defective vasculogenesis in systemic sclerosis , 2004, The Lancet.

[15]  Till Acker,et al.  Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.

[16]  Barbara Bottazzi,et al.  PTX3 inhibits angiogenesis Selective recognition of fibroblast growth factor-2 by the long pentraxin , 2013 .

[17]  Maurizio Cutolo,et al.  Raynaud's phenomenon and the role of capillaroscopy. , 2003, Arthritis and rheumatism.

[18]  H. Chapman,et al.  Urokinase receptor and integrin interactions. , 2003, Current pharmaceutical design.

[19]  C. Billottet,et al.  Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2 , 2002, Oncogene.

[20]  F. Blasi,et al.  Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor , 2002, Thrombosis and Haemostasis.

[21]  Marco Presta,et al.  Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells , 2001, Oncogene.

[22]  N. Ferrara.  VEGF: an update on biological and therapeutic aspects. , 2000, Current opinion in biotechnology.

[23]  M. Mizumoto,et al.  Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  P. Carmeliet,et al.  Transgenic mouse models in angiogenesis and cardiovascular disease , 2000, The Journal of pathology.

[25]  P. Hogg,et al.  Angiostatin Formation Involves Disulfide Bond Reduction and Proteolysis in Kringle 5 of Plasmin* , 1999, The Journal of Biological Chemistry.

[26]  Daniel B. Rifkin,et al.  Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis , 1998, The Journal of cell biology.

[27]  S. Mandriota,et al.  Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. , 1997, Journal of cell science.

[28]  P. Hogg,et al.  Generation of Angiostatin by Reduction and Proteolysis of Plasmin , 1997, The Journal of Biological Chemistry.

[29]  E. Leroy.  SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .

[30]  M. Stack,et al.  Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. , 1996, Cancer research.

[31]  S. Mandriota,et al.  Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.